Adjacent Therapy Programs

About ALK Abello

ALK Abelló's mission is to pioneer allergy immunotherapy solutions that improve and protect the lives of people with allergies globally. The company has achieved a dominant position in the AIT market through its proprietary sublingual tablet technology and a robust commercial portfolio. Its 'Allergy+' strategy for 2024-2028 focuses on expanding its patient reach, advancing a novel pipeline in food allergy and anaphylaxis, and leveraging digital innovation, as evidenced by strong 2025 financials with 15% revenue growth and a 26% EBIT margin.

Therapeutic Areas